18 results about "Elongation factor" patented technology

The present disclosure relates to pharmaceutical compositions comprising a synthetic transcription elongation factor (SynTEF) and an epigenetic inhibitor (e.g., a histone deacetylase (HDAC) inhibitor). As detailed herein, the disclosed compositions and combinations can be used to target FGF14b in Friedreich's ataxia (FRDA / FA), SCA27b, and other GAA-repeat based diseases.

The present disclosure provides DNA molecules, such as transfer plasmids, useful for manufacturing packaged retroviral vectors encoding a therapeutic protein such as chimeric antigen receptors (CARs) and T cell receptors (TCRs). The encoded retroviral transcript in the DNA molecule includes a transgene, an elongation factor 1-alpha 1 (EFla) promoter, without the EFla intron, operably linked to the transgene and a Rev response element (RRE).

A compound derivative is provided, where R in the compound of formula A is piperidine, and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.

A compound derivative is provided, where R in the compound of formula A is (2-(2-(piperidin-1-yl)ethane-1-amine), and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.

To provide a method for rescuing a termination codon through genetic reassignment using ACE-tRNA.SOLUTION: In certain embodiments, the invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon arm, and an acceptor arm, wherein the T-arm comprises a T-stem having a nucleotide that interacts with elongation factor 1 alpha 1 (EF1 alpha). EF1 alpha recruits aminoacyl-tRNAs to the ribosome and protects the tRNA from being deacylated. Rational nucleotide substitutions result in tuned tRNA: EF1 α interactions that enhance tRNA delivery to the ribosome and protection from de-acylation.SELECTED DRAWING: None

The present invention relates to a vaccine composition for preventing malaria, comprising, as an active ingredient, an elongation factor-2 (EF-2) recombinant protein derived from Plasmodium falciparum and, more specifically, to a vaccine composition for preventing malaria, comprising, as an active ingredient, EF-2 recombinant peptides derived from Plasmodium falciparum consisting of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2, respectively, and use thereof.

In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, wherein the T-arm comprises nucleotides that interact with the elongation factor 1 alpha protein, and methods of use thereof. In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, (a) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UCA-3′ and recognizes TGA stop codons, and wherein the acceptor arm is operably linked to a arginine, tryptophan or glycine; (b) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UUA-3′ and recognizes TAA stop codons, and wherein the acceptor arm is operably linked to a glutamine or, glutamate; or (c) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-CUA-3′ and recognizes TAG stop codons, and wherein the acceptor arm is operably linked to a tryptophan, glutamate or glutamine.

This invention belongs to the fields of plant genetic engineering and biotechnology, and discloses a peanut endogenous strong promoter P. AhEF1α Its preparation methods and applications. Promoters include P AhEF1α‑1 P AhEF1α‑2 P AhEF1α‑3 and P AhEF1α‑4 This invention uses the Arabidopsis EF1α gene amino acid sequence as a reference, identifies candidate peanut EF1α genes through homology search, screens high-expression genes by expression level analysis, and clones the aforementioned promoter from the peanut genome of Yuhua 9326 using PCR technology. A recombinant vector containing this promoter is constructed and transformed into peanut embryogenic callus tissue. Functional verification shows that the promoter can efficiently drive the expression of downstream genes in peanut callus. This invention solves the technical bottleneck of existing peanut gene editing technologies that rely on exogenous promoters and have poor adaptability, fills the gap in the application of strong endogenous promoters in peanuts, and can be used to construct a precise gene editing system for peanuts, promoting stress-resistant, high-quality, and grade-equal peanut varieties. It has significant practical value and industrialization prospects.

The application belongs to the technical field of plant genetic engineering, and particularly relates to an extension factor subunit OsELP4 gene for regulating rice blast resistance and application. An extension factor subunit OsELP4 gene induced by Magnaporthe oryzae is screened, the nucleotide sequence of the gene is shown as SEQ ID NO:1, and the protein sequence coded by the gene is shown as SEQ ID NO:2. By using Agrobacterium-mediated transformation, an OsELP4 overexpression transgenic line and a CRISPR / Cas9 mutant line are obtained. It is found by inoculating and identifying the transgenic materials with rice blast that the OsELP4 overexpression line has enhanced resistance to rice blast, and the mutant line is more susceptible to rice blast, which indicates that OsELP4 is a positive regulation factor for rice resistance to rice blast. OsELP4 plays a positive regulation role in rice resistance to rice blast, and overexpression of the gene can significantly improve the resistance of rice to rice blast.

In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, wherein the T-arm comprises nucleotides that interact with the elongation factor 1 alpha protein, and methods of use thereof. In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, (a) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UCA-3′ and recognizes TGA stop codons, and wherein the acceptor arm is operably linked to a arginine, tryptophan or glycine; (b) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UUA-3′ and recognizes TAA stop codons, and wherein the acceptor arm is operably linked to a glutamine or, glutamate; or (c) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-CUA-3′ and recognizes TAG stop codons, and wherein the acceptor arm is operably linked to a tryptophan, glutamate or glutamine.

The invention provides a genetic expression cassette comprising, in order from 5'-3':an 5' adenoassociated viral (AAV) inverted terminal repeat (ITR), the elongation factor 1 long promoter, a chimeric intron, a 5' UT translational enhancer element containing a Kozak sequence, a polynucleotide comprising a nucleic acid sequence with at least 80% identity to the nucleic acid sequence of either wild-type of propionyl-CoA carboxylase beta (PCCB or synPCCB1), the hepatitis B virus derived post-translational response element, the bovine growth hormone poly-adenylation sequence, and an 3' AAV inverted ITR. The invention also provides expression vectors comprising the inventive cassette, compositions comprising the same, and methods for treating a disease or condition mediated by propionyl-CoA carboxylase.

The application belongs to the technical field of plant genetic engineering, and particularly relates to an extension factor subunit OsRAV9 gene for regulating rice blast resistance and application. An extension factor subunit OsRAV9 gene induced by Magnaporthe oryzae is screened, the nucleotide sequence of the gene is shown as SEQ ID NO:1, and the protein sequence coded by the gene is shown as SEQ ID NO:2. By using Agrobacterium-mediated transformation, an OsRAV9 overexpression transgenic line and a CRISPR / Cas9 mutant line are obtained. It is found by inoculating and identifying the transgenic materials with rice blast that the OsRAV9 overexpression line has enhanced resistance to rice blast, and the mutant line is more susceptible to Magnaporthe oryzae, which indicates that OsRAV9 is a positive regulation factor for rice resistance to rice blast. The OsRAV9 gene plays a positive regulation role in rice resistance to rice blast, and overexpression of the gene can significantly improve the resistance of rice to rice blast.

The invention discloses a pathogen infection diagnosis marker based on DPH gene family mRNA and diphtheria amide modification level, a kit and application. The marker combination comprises the mRNA expression level of the DPH1-DPH7 gene and the diphtheria amide modification level of the eukaryotic elongation factor 2. The invention reveals that the combination is remarkably related to pathogen infection for the first time, and provides a detection kit containing a specific primer, biotinylated NAD, pseudomonas exotoxin A and other reagents. The indexes are respectively detected through qPCR (quantitative polymerase chain reaction) and non-denatured immunoblotting, and efficient diagnosis can be realized through combined analysis. Experiments show that the combined marker is excellent in diagnostic performance, the area AUC under a curve of a combined logistic regression model can reach 0.917, the sensitivity is 90.9%, the specificity is 85.7%, and a novel and reliable molecular scheme is provided for early-stage differential diagnosis of infection.

The present disclosure provides DNA molecules, such as transfer plasmids, useful for manufacturing packaged retroviral vectors encoding a therapeutic protein such as chimeric antigen receptors (CARs) and T cell receptors (TCRs). The encoded retroviral transcript in the DNA molecule includes a transgene, an elongation factor 1-alpha 1 (EF1α) promoter, without the EF1α intron, operably linked to the transgene and a Rev response element (RRE).

A compound derivative is provided, where R in the compound of formula A is 4-methylpiperazine, and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.

The present invention relates to tRNA-based effector molecules having generally non-natural modifications and related methods. This disclosure features modified tRNA-based effector molecules (TREMs, e.g., TREM or TREM fragments), as well as related compositions and uses. TREMs are complex molecules capable of mediating various cellular processes. For example, the TREMs described herein may have: (i) the ability to assist in protein synthesis, (ii) the ability to be loaded by tRNA synthetases, (iii) the ability to be bound by elongation factors, (iv) the ability to introduce amino acids into peptide chains, (v) the ability to assist in protein elongation, or (vi) the ability to assist in initiating protein synthesis, for example, in cells.

The invention relates to a construction method of reversible immortalized human mesenchymal stem cells (ihBMSCs), which comprises the following steps: constructing a hybrid promoter hEFH formed by fusing a human elongation factor 1 alpha and an HTLV-1 promoter, human telomerase reverse transcriptase (hTERT) and a recombinant lentiviral vector containing FRT sites at two ends of the hTERT, and packaging to obtain a recombinant lentivirus; the lentivirus is used for infecting primary human bone marrow mesenchymal stem cells to obtain the ihBMSCs. Compared with primary cells, the ihBMSCs disclosed by the invention have strong in-vitro proliferation capacity and high activity, the immortalized phenotype can be recognized by an FLP-FRT system and is subjected to condition knockout so as to realize reversible deimmortalization, and the ihBMSCs have biosafety phenotypes with low immunogenicity and no tumorigenicity in vivo and can be induced to form bones in vivo and in vitro. In conclusion, the invention provides a reliable and safe seed cell for bone tissue engineering, and the seed cell has a huge application prospect in the field of stem cell treatment.

The present disclosure provides a method for purifying rubber elongation factor protein, which comprises: obtaining rubber particles from Hevea brasiliensis latex and dispersing the rubber particles in a buffer solution; extracting rubber particle protein using an extraction solution containing a non-ionic detergent; adding ammonium sulfate and an alcohol reagent to the extraction solution containing the rubber particle protein to precipitate the rubber particle protein (mainly rubber elongation factor protein); and separating the extracted rubber particle protein by gel filtration chromatography to obtain purified rubber elongation factor protein. The method for purifying rubber elongation factor protein can expand the purification scale and obtain milligram-level high-purity rubber elongation factor protein.